This alteration in MYO1F expression parallels changes observed in established AD- and FTD/ALS-associated risk genes, such as TREM2 and GRN (Matarin et al., 2015; Zhang et al., 2020). The gene discussed is MYO1F; the disease is amyotrophic lateral sclerosis.